Showing results (151-160 of 279) with videos related to

Sort By:
Pageof 28
Clinical Proteomics|April 17, 2015
Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancerHenrik J Johansson, Betzabe C Sanchez, Jenny Forshed, et al.
Breast (Edinburgh, Scotland)|February 17, 2012
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancerJonas Bergh, Gabriella Mariani, Fatima Cardoso, et al.
Oncoimmunology|September 20, 2018
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancerAlexios Matikas, John Lövrot, Anna Ramberg, et al.
Breast Cancer Research and Treatment|September 15, 2016
Long-term outcome in young women with breast cancer: a population-based studyHanna Fredholm, Kristina Magnusson, Linda S Lindström, et al.
Human Reproduction (Oxford, England)|April 22, 2020
Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter studyAnna Marklund, Sandra Eloranta, Ida Wikander, et al.
The Journal of Clinical Investigation|February 27, 2018
Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodesIkram Ullah, Govindasamy-Muralidharan Karthik, Amjad Alkodsi, et al.
The New England Journal of Medicine|November 9, 2017
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 YearsHongchao Pan, Richard Gray, Jeremy Braybrooke, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2007
Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancerBent Ejlertsen, Henning T Mouridsen, Maj-Britt Jensen, et al.
Elife|March 16, 2022
Risk of heart disease following treatment for breast cancer - results from a population-based cohort studyHaomin Yang, Nirmala Bhoo-Pathy, Judith S Brand, et al.
The Lancet Regional Health. Europe|October 13, 2025
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based studyXingrong Liu, Behnaz Binicy, Balazs Acs, et al.
Pageof 28